deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05249127

64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA) (COBRA)

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 1/2 Study of Participants With Biochemical Recurrence of Prostate Cancer

Sponsor: Clarity Pharmaceuticals Ltd

Conditions Biochemical Recurrence of Malignant Neoplasm of Prostate
Interventions 64Cu-SAR-bisPSMA
Updated 12 times since 2022 Last updated: Sep 5, 2024 Started: Apr 11, 2022 Primary completion: Aug 8, 2023 Completion: Aug 8, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Biochemical Recurrence of Malignant Neoplasm of Prostate and is currently completed. Clarity Pharmaceuticals Ltd leads this study, which shows 12 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2022 – ~May 2022 · 2 months · monthly snapshotNot Yet Recruiting~May 2022 – ~Jun 2022 · 31 days · monthly snapshotRecruiting~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshotRecruiting~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshotRecruiting~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshotRecruiting~Nov 2022 – ~Apr 2023 · 5 months · monthly snapshotRecruiting~Apr 2023 – ~Sep 2023 · 5 months · monthly snapshotActive Not Recruiting~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshotCompleted~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshotCompleted~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshotCompleted~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshotCompleted~Oct 2024 – present · 21 months · monthly snapshotCompleted

Change History

12 versions recorded

  1. Oct 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Oct 2024 [monthly]

    Completed PHASE1/PHASE2

  3. Aug 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

  4. Jul 2024 — Aug 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Sep 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 7 earlier versions

  1. Apr 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Nov 2022 — Apr 2023 [monthly]

    Recruiting PHASE1_PHASE2

  3. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE1_PHASE2

  6. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Mar 2022 — May 2022 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Clarity Pharmaceuticals Ltd
Data source: Clarity Pharmaceuticals Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations